India Keeps Eye On SGLT2 Inhibitors Amid Safety Signals
After recent safety warnings from both US FDA and Health Canada, India steps ups surveillance, but Janssen and AstraZeneca tell Pink Sheet that data indicate no major safety concerns, at least so far.